Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | $45.00 | Outperform | Noble Capital Markets |
| 9/1/2021 | $78.00 | Buy | HC Wainwright & Co. |
STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US. The Phase III clinical trial has recently been activated at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States – specifically at its network sites in Los Angeles and Orange counties, Arizona, Atlanta, and Illinois. Principal investigator at City of Hop
STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the upcoming AACR Meeting 2026. Two abstracts and two posters were accepted for presentation. The titles and authors of the abstracts are as follows: Abstract Number: CT138 - Poster Section 52 on April 20, 2026, 2-5pm Abstract Title: Preliminary delayed-type-hypersensitivity immune response results from open-label arm of on-going Phase III study to
STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided a preliminary update showing a continued reduction in the recurrence rate in the fully enrolled, 250 patient, open label non-HLA-A*02 arm of FLAMINGO-01. 6 Months of Additional Patient Data Since Last Update Shows Recurrence Rate of <1% per Year in Non-HLA-A*02 Patients Treated with GLSI-100, Following Completion of Primary Immunization Series (PIS)This <1% Annual Recurrence Rate Obser
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
8-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)
DEFA14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
Noble Capital Markets initiated coverage of Greenwich LifeSciences with a rating of Outperform and set a new price target of $45.00
HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00
Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00
SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)